Fengtao You

1.1k total citations · 1 hit paper
17 papers, 651 citations indexed

About

Fengtao You is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Fengtao You has authored 17 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Immunology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Fengtao You's work include CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (7 papers) and Immunotherapy and Immune Responses (3 papers). Fengtao You is often cited by papers focused on CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (7 papers) and Immunotherapy and Immune Responses (3 papers). Fengtao You collaborates with scholars based in China, United Kingdom and Pakistan. Fengtao You's co-authors include Lin Yang, Xiaowen Tang, Wenhong Shen, Ting Xu, Jia Yin, Haiping Dai, Guanghua Chen, Depei Wu, Xiaming Zhu and Jianhua Yu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fengtao You

16 papers receiving 644 citations

Hit Papers

Erratum: First-in-man clinical trial of CAR NK-92 cells: ... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
    2018 356 citations Xiaowen Tang, Lin Yang et al. PubMed profile →

Peers

Fengtao You
Liora M. Schultz United States
Lisa Marie Serrano United States
Elizabeth Veloso United States
Silke Landmeier Germany
Elisabetta Cribioli Switzerland
Yvette Bernal United States
Jiazhen Cui China
Silke Frenz Germany
Feiyan Mo United States
Mingzhi Zhang China
Liora M. Schultz United States
Fengtao You
Citations per year, relative to Fengtao You Fengtao You (= 1×) peers Liora M. Schultz

Countries citing papers authored by Fengtao You

Since Specialization
Citations

This map shows the geographic impact of Fengtao You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengtao You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengtao You more than expected).

Fields of papers citing papers by Fengtao You

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengtao You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengtao You. The network helps show where Fengtao You may publish in the future.

Co-authorship network of co-authors of Fengtao You

This figure shows the co-authorship network connecting the top 25 collaborators of Fengtao You. A scholar is included among the top collaborators of Fengtao You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengtao You. Fengtao You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Deng, Qing, Fengtao You, Huanli Sun, et al.. (2025). Vincristine/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia. Acta Biomaterialia. 200. 641–652.
2.
Jiang, Licui, Fengtao You, Changsong Qi, et al.. (2024). B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors. Cancer Research. 84(23). 4066–4080. 7 indexed citations
3.
Hu, Lijuan, Hui Yu, Heng Mei, et al.. (2024). Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.. Journal of Clinical Oncology. 42(16_suppl). 6515–6515. 2 indexed citations
4.
Dong, Yangyang, Fengtao You, Yifan Zhang, et al.. (2024). CD7 Nanobody-Based Immuno-Nanotoxin for Targeted Treatment of T-Cell Acute Lymphoblastic Leukemia. ACS Applied Nano Materials. 7(7). 7195–7202. 2 indexed citations
5.
Wang, Tian, Fengtao You, Tingting Zhang, et al.. (2023). B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia. European journal of medical research. 28(1). 129–129. 8 indexed citations
6.
Zhang, Kailu, Zixuan Li, Tian Wang, et al.. (2023). CD7 protein plays a crucial role in T cell infiltration in tumors. Heliyon. 9(6). e16961–e16961. 3 indexed citations
7.
Wang, Tian, et al.. (2023). Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. Life Sciences. 331. 122024–122024. 14 indexed citations
8.
Zhang, Tingting, Tian Wang, Fengtao You, et al.. (2022). Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transplant Immunology. 71. 101538–101538. 13 indexed citations
9.
You, Fengtao, Licui Jiang, Dan Chen, et al.. (2021). MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.. American Journal of Cancer Research. 11(1). 79–91. 25 indexed citations
10.
Zhu, Xinying, Xin Liu, Xingbing Wang, et al.. (2020). [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].. PubMed. 28(4). 1367–1375. 5 indexed citations
11.
Ji, Cheng, Fengtao You, Tingting Zhang, et al.. (2020). Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma. SHILAP Revista de lepidopterología. 18. 3254696951–3254696951. 2 indexed citations
12.
Zhang, Mingzhi, Lin Yang, Xiaorui Fu, et al.. (2020). First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. Journal of Clinical Oncology. 38(15_suppl). 3026–3026. 18 indexed citations
13.
Wang, Min, Fengtao You, Xingbing Wang, et al.. (2019). Automation Platform for CAR-T Manufacturing: The Benefits and the Clinical Outcomes. Blood. 134(Supplement_1). 1960–1960. 4 indexed citations
14.
Xue, Lei, Min Wang, Ping Qiang, et al.. (2019). <p>Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma</p>. OncoTargets and Therapy. Volume 12. 5627–5638. 39 indexed citations
15.
You, Fengtao, Yinyan Wang, Licui Jiang, et al.. (2019). A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.. PubMed. 9(1). 64–78. 116 indexed citations
16.
17.
Chen, Ying, Fengtao You, Licui Jiang, et al.. (2017). Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget. 8(23). 37128–37139. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Lisa Marie Serrano Breakdown of academic impact, for papers by Elizabeth Veloso Breakdown of academic impact, for papers by Silke Landmeier Breakdown of academic impact, for papers by Elisabetta Cribioli Breakdown of academic impact, for papers by Yvette Bernal Breakdown of academic impact, for papers by Jiazhen Cui Breakdown of academic impact, for papers by Silke Frenz Breakdown of academic impact, for papers by Feiyan Mo Breakdown of academic impact, for papers by Mingzhi Zhang
Rankless by CCL
2026